Skip to Content
Join the 'Daclatasvir' group to help and get support from people like you.

Daclatasvir News

FDA Medwatch Alert: Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating

ISSUE: The FDA is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain...

FDA Approves Expanded Use of Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

PRINCETON, N.J., February 5, 2016 --(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that Daklinza (daclatasvir, 60 mg), an NS5A replication complex inhibitor, has been...

FDA Approves Daklinza (daclatasvir) for Chronic Hepatitis C Genotype 3 Infections

July 24, 2015 – The U.S. Food and Drug Administration today approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections. Daklinza is the first drug...

Ask a Question

Want to post your own question to this support group? You'll need to first create an account with Drugs.com (or sign in to your existing account).

Further Information

Related Condition Support Groups

Hepatitis C

Daclatasvir Patient Information at Drugs.com